Artiva Q1 FY26 net loss widens to $23.5 million

Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics, Inc.

ARTV

0.00
  • Artiva Biotherapeutics posted a wider first-quarter net loss of $23.5 million, or $0.95 per share, versus a loss of $20.3 million, or $0.83 per share, a year earlier.
  • R&D expense climbed to $19.3 million from $17.1 million, while other income, net, fell to $0.9 million from $1.9 million.
  • Cash, cash equivalents and investments slid to $86.8 million as of March 31, 2026, from $108 million at end-2025, with runway expected into Q2 2027.
  • FDA alignment reached on a single Phase 3 registrational trial in refractory rheumatoid arthritis of AlloNK plus rituximab versus rituximab alone in about 150 patients, with initiation planned for H2 2026.
  • Initial Phase 2a basket-trial data showed 71% ACR50 responses at six months in seven refractory RA patients, with no CRS or ICANS reported as of April 3 data cutoff.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605080631PRIMZONEFULLFEED9716082) on May 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.